Status:
COMPLETED
Evaluation Of The Effect Of SGLT-2 Inhibitors On Atrial Fibrillation Recurrence In Diabetic Patients
Lead Sponsor:
Bursa Postgraduate Hospital
Conditions:
Diabetes Mellitus
Atrial Fibrillation (AF)
Eligibility:
All Genders
18-90 years
Brief Summary
Consecutive DCCV was performed until to achieve 120 patients in SR (60 DM patients who used SGLT-2 inhibitors and 60 DM patients who did not use SGLT-2 inhibitors). Patients defined as SGLT-2 inhibito...
Eligibility Criteria
Inclusion
- patients \> 18 years and \< 90 years,
- Patient diagnosed with DM
- Patient underwent electrical cardioversion due to AF and was restored to sinus rhythm
Exclusion
- patient who are not suitable for anticoagulant use,
- have thyroid dysfunction,
- glomerular filtration rate ≤ 25 ml/min/1.73 m²,
- patients whose sinus rhythm cannot be achieved with electrical cardioversion,
- malignancy patients,
- patients with acute or chronic inflammatory disease,
- patients with peripheral artery disease,
- patients with pacemakers,
- patients with advanced valve stenosis or insufficiency,
- patients who have had coronary bypass surgery,
- patients with percutaneous or surgical bioprosthesis or metallic valve surgery.
Key Trial Info
Start Date :
October 2 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 2 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06951737
Start Date
October 2 2022
End Date
October 2 2024
Last Update
June 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bursa Yüksek İhtisas Hastanesi
Bursa, Turkey (Türkiye)